Consensus differences of HIV-1 Gag between 454 and Sanger clone-based sequencing methods overlapped with the functional of immunogenic sites in individuals.

Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression

ABSTRACT There are marked differences in the spread and prevalence of HIV-1

Non synonymous substitutions in HIV-1 GAG are frequent in epitopes outside the major hydrophobic region and associated with subtype differences

Abstract In 2018, an estimated 38 million people lived with HIV-1 infection result

Non-synonymous Substitutions in HIV-1 GAG Are Frequent in Epitopes Outside the Functionally Conserved Regions and Associated With Subtype Differences

In 2019, 38 million people lived with HIV-1 infection resulting in 690,000 deaths. Over 50% of this

A20 Deep sequencing reveals viral evolution in GAG within protective HLA Alleles B*57: 02, B*58: 01, and B*7 supertype individuals acutely infected with HIV-1 subtype C in Durban, South Africa

Recognition of HIV-1 Gag peptides from clades A, B, C_Du422, C_CH and D sequences in HIV-1 clade C infected individuals from South Africa.

(A) Total magnitude of Gag-specific T-cells (SFU/10⁶ PBMC) against individual peptides

Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing

Abstract Baseline plasma samples of 490 randomly selected antiretroviral therapy (ART) naïve patien